Studies on ovarian carcinoma cell lines have revealed an association between high BCL-2 levels and resistance to cisplatin (Eliopoulos et al, 1995; Herod et al, 1996; Jones et al, 1998), however, contradictory results have been published, too (Beale et al, 2000); BAX expression either enhanced or did not influence ovarian carcinoma cell lines sensitivity to cisplatin (Jones et al, 1998; Beale et al, 2000). The gene discussed is BAX; the disease is ovarian carcinoma.